FeesSafety
Pluang+

Vanguard U.S. Value Factor ETF rated Hold due to weak growth and limited AI exposure.

Analyst Insights
19 Nov 2026, 08:17 WIB
Seeking Alpha
View Source
Neutral
Vanguard U.S. Value Factor ETF rated Hold due to weak growth and limited AI exposure.

The Vanguard U.S. Value Factor ETF (VFVA) is rated as a Hold because of its weak earnings growth prospects and modest expected interest rate tightening. With a forward P/E of 10x and an expected 2.5% earnings growth for the Russell 1000 Value Index by 2027, the fund's value-oriented portfolio may benefit from rising rates and financial sector exposure but lacks significant AI-related growth drivers. VFVA has returned 20.8% year-to-date, outperforming the SPY's 8.2%, yet its limited exposure to AI could limit future relative gains if market sentiment shifts back to growth leaders.

The Vanguard U.S. Value Factor ETF (VFVA) is the subject, presented here with related market data for context. For readers following US stocks on Pluang, 62 of 150 priced stocks rose while 87 fell today. Notable movers include NEM at USD 103.00 with a 7.42% decline and 89% sell activity, GFI at USD 33.39 down 6.97% with 65% buy activity, and SPCE at USD 1.21 down 6.92% with 95% buy activity. This snapshot is as of Nov 19, 2026 11:02 WIB.

More News

ArcaTrader launches 24/7 perpetuals trading for brokers and prop firms via Hyperliquid.

ArcaTrader launches 24/7 perpetuals trading for brokers and prop firms via Hyperliquid.

ArcaTrader has introduced 24/7 perpetuals trading powered by Hyperliquid on its multi-asset platform, allowing brokers and prop firms to offer continuous perpetuals alongside CFDs through one integrated system. This expansion enhances ArcaTrader's ex...

Others
Bullish
1 hour ago
Tempus AI reports 23% revenue growth and $193M from new data deals over 5 years

Tempus AI reports 23% revenue growth and $193M from new data deals over 5 years

Tempus AI reported a 23% year-over-year revenue increase to $411.5 million in Q3 2026, driven by rising test prices and multiyear biopharma licensing agreements expected to generate $193 million over five years. The company also anticipates an $80 mi...

Company Fundamentals
Bullish
1 hour ago
Planet Labs secures new rocket launches from Stoke Space as SpaceX plans to retire Falcon 9 by 2028

Planet Labs secures new rocket launches from Stoke Space as SpaceX plans to retire Falcon 9 by 2028

Planet Labs, which operates the largest Earth observation satellite fleet, faces a challenge as SpaceX plans to retire its Falcon 9 rockets by 2028. To maintain its satellite launches, Planet Labs has signed a multi-launch agreement with Stoke Space ...

Market News
Bullish
1 hour ago
Sigma Lithium cuts short-term debt 85%, targets 330,000 tons lithium production in 2027 with low costs.

Sigma Lithium cuts short-term debt 85%, targets 330,000 tons lithium production in 2027 with low costs.

Sigma Lithium reduced its short-term debt by 85% through a $125 million convertible note refinancing, easing financial pressure for expansion. The company reported low all-in sustaining costs of $642 per ton, well below the average lithium price of $...

Company Fundamentals
Bullish
1 hour ago
Novartis forecasts 5% sales growth CAGR through 2031 with upgraded peak sales for key drugs.

Novartis forecasts 5% sales growth CAGR through 2031 with upgraded peak sales for key drugs.

Novartis projects a 5% compound annual growth rate (CAGR) in net sales from 2026 to 2031 and aims to restore its core operating income margin to over 40% by 2029. The company raised peak sales forecasts for key drugs Kesimpta, Scemblix, and Leqvio, r...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App